Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TOL2
- Development stage
- Unknown
- Lead developer
- Toleranzia
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
TOL2 is a recombinant fusion protein being developed by Toleranzia AB as a disease-modifying treatment for generalized myasthenia gravis (gMG). The therapy utilizes Toleranzia's proprietary technology platform to induce immunological tolerance. It consists of a modified cholera toxin B subunit (CTB) carrier protein fused to the alpha-subunit of the human acetylcholine receptor (AChR). TOL2 is designed to selectively reprogram the immune system to stop attacking the AChR at the neuromuscular junction, potentially offering a long-term cure or significant reduction in symptoms without the side effects associated with broad immunosuppressants.
- Other names
- recombinant mutated extracellular domain of human acetylcholine receptor alpha1 subunitAChR-alpha1-ECDAChR-alpha-1-ECDAChR-alpha 1-ECD
02
Targets
CHRNA1 (nAChR α1 subunit)Acetylcholine receptor-specific autoantibodies and cognate B-cell receptors
Beyond the preview
Go deeper on TOL2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TOL2.